| Tue, 14 Aug 2018 14:23:37: | AIDS health group brings Gilead patent skirmish to Supreme Court
|
| Tue, 14 Aug 2018 13:59:59: | Pfizer joins DOJ probe into claims pharma bribes funded Iraqi terrorists
|
| Tue, 14 Aug 2018 13:59:07: | Allergan taps Pfizer oncology veteran as CMO for some crucial pipeline help
|
| Mon, 13 Aug 2018 20:09:54: | NICE cost watchdogs spurn Biogen's pricey Spinraza but leave door open for a deal
|
| Mon, 13 Aug 2018 19:35:22: | Bavarian Nordic secures €30M loan as it expands plant to bring Imvamune manufacturing entirely in-house
|
| Mon, 13 Aug 2018 15:28:30: | Roche's Xolair, challenged in asthma, wins 'breakthrough' in food allergies
|
| Mon, 13 Aug 2018 14:05:01: | CVS' move to lean on ICER data could mean dramatic shift in drug pricing leverage
|
| Mon, 13 Aug 2018 13:42:17: | Alnylam vows value-based pricing, financial help with $450K Onpattro launch
|
| Mon, 13 Aug 2018 11:57:54: | J&J loses early bid to escape Pfizer's Remicade biosimilars lawsuit
|
| Sat, 11 Aug 2018 22:13:40: | Outcome's image rehab rolls on with Nielsen deal for first-ever POC audience tallies
|
| Sat, 11 Aug 2018 16:13:39: | Salix, US WorldMeds eye 2019 push into the mainstream for opioid withdrawal drug Lucemyra
|
| Fri, 10 Aug 2018 15:26:23: | FDA found big problems a year ago at Chinese plant now recalling tainted valsartan
|
| Fri, 10 Aug 2018 15:05:42: | States say Alvogen lawsuit is part of a 'guerilla' war against the death penalty
|
| Fri, 10 Aug 2018 14:26:28: | Express Scripts’ new formulary ejects some drugs once thought 'untouchable': analysts
|
| Fri, 10 Aug 2018 14:03:09: | Pfizer's Besponsa, Lilly's Taltz rack up reimbursement wins at NICE
|
| Fri, 10 Aug 2018 13:16:52: | Amid pricing spat with U.K. government, Vertex won't ask NICE to approve its new CF drug
|
| Fri, 10 Aug 2018 04:32:06: | FiercePharmaAsia—Lenvima growth; China’s drug invite; Samsung’s biologics commitment
|
| Thu, 09 Aug 2018 19:02:48: | Step therapy changes at Medicare Part B to hit Amgen, Regeneron particularly hard: analysts
|
| Thu, 09 Aug 2018 15:21:54: | Can a strategic review solve Mylan's problems? Don't count on it
|
| Thu, 09 Aug 2018 15:11:25: | Bausch Health aims top-seller Xifaxan at new diseases to pump up growth
|
| Thu, 09 Aug 2018 14:44:46: | FDA approves first generic under new pathway designed to fight drug price gouging
|
| Thu, 09 Aug 2018 13:33:39: | Mylan says plant remediation dictated in part by which generics to drop
|
| Thu, 09 Aug 2018 13:28:15: | Citing appeals court 'anarchy,' Amgen asks SCOTUS to weigh its PCSK9 patent spat with Sanofi
|
| Thu, 09 Aug 2018 13:24:22: | Struggling Perrigo OKs plan to hive off prescription business
|
| Thu, 09 Aug 2018 13:21:56: | China targets Cosentyx, Shingrix and Luxturna and 45 other drugs for priority approval
|
